Search Results - Patel, Poulam, Prof

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    OP15. ENHANCEMENT OF MYELOID DENDRITIC CELLS THROUGH MAPK P38 INHIBITION PROMOTES T CELL PROLIFERATION AND RESTORES ADAPTIVE IMMUNITY IN GBM PATIENTS

    OP15. ENHANCEMENT OF MYELOID DENDRITIC CELLS THROUGH MAPK P38 INHIBITION PROMOTES T CELL PROLIFERATION AND RESTORES ADAPTIVE IMMUNITY IN GBM PATIENTS by Adhikaree, Dr Jason, Jackson, Dr Andrew, Patel, Prof Poulam

    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial

    Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU... by Gore, Martin E, Prof, Griffin, Clare L, MSc, Hancock, Barry, Prof, Patel, Poulam M, Prof, Pyle, Lynda, BSc, Aitchison, Michael, MD, James, Nicholas, Prof, Oliver, Roderick TD, Prof, Mardiak, Jozef, MD, Hussain, Tahera, DPhil, Sylvester, Richard, ScD, Parmar, Mahesh KB, Prof, Royston, Patrick, Prof, Mulders, Peter FA, Prof

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials

    Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials by Flaherty, Keith T, MD, Hennig, Michael, PhD, Lee, Sandra J, PhD, Ascierto, Paolo A, MD, Dummer, Reinhard, Prof, Eggermont, Alexander M M, Prof, Hauschild, Axel, MD, Kefford, Richard, Prof, Kirkwood, John M, Prof, Long, Georgina V, PhD, Lorigan, Paul, MD, Mackensen, Andreas, Prof, McArthur, Grant, PhD, O'Day, Steven, MD, Patel, Poulam M, MD, Robert, Caroline, PhD, Schadendorf, Dirk, Prof

    Published in The lancet oncology
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

    Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-infer... by Brown, Janet E, Prof, Royle, Kara-Louise, MSc, Gregory, Walter, Prof, Ralph, Christy, PhD, Maraveyas, Anthony, Prof, Din, Omar, MD, Eisen, Timothy, Prof, Nathan, Paul, Prof, Powles, Tom, Prof, Griffiths, Richard, FRCP, Jones, Robert, Prof, Vasudev, Naveen, PhD MBChB, Wheater, Matthew, FRCP PhD, Hamid, Abdel, FRCR MSc, Waddell, Tom, MD, McMenemin, Rhona, MSc FRCR, Patel, Poulam, Prof, Larkin, James, Prof, Faust, Guy, MD, Martin, Adam, PhD, Swain, Jayne, PhD, Bestall, Janine, PhD, McCabe, Christopher, Prof, Meads, David, PhD, Goh, Vicky, Prof, Min Wah, Tze, Prof, Brown, Julia, Prof, Hewison, Jenny, Prof, Selby, Peter, Prof, Collinson, Fiona, MD

    Published in The lancet oncology
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: